Clinical trials: NMOSD
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack
Diagnosis of ON With or Without MS or NMOSD
This is both a prospective and retrospective study of patients with a known diagnosis of optic neuritis (ON) only, multiple sclerosis (MS) with ON, or neuromyelitis spectrum disorder (NMOSD) with ON.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression
- Trial name
- NCT04131764
- Testing
- Reflex (Brightlamp Inc., Purdue University)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Jagannadha R Avasarala
Multiple Sclerosis, Neuromyelitis Optica
MS and NMOSD in African-Americans
This is a prospective study that aims to collect and review neuromyelitis optica spectrum disorder (NMOSD) data from African American patients with a known diagnosis of multiple sclerosis (MS).
- Trial name
- NCT04131673
- Where
- United States
- Sponsor
- Jagannadha R Avasarala
NMO Spectrum Disorder
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD)…
- Trial name
- NCT07377305
- Testing
- 10Hz tTIS (2-4mA) Intervention
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab…
- Trial name
- SAkuraBonsai (NCT05269667)
- Testing
- Satralizumab 120 mg
- Where
- 3 sites in United States, South Korea and 1 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
- Trial name
- NCT07341828
- Testing
- CD20/BCMA-directed CAR-T cells
- Volunteers
- 15 people
- Sponsor
- Huashan Hospital
Neuromyelitis Optica
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.
- Trial name
- NCT05356858
- Testing
- zanubrutinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xuanwu Hospital, Beijing
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
The objectives of this time-to-event study are to assess the efficacy and safety of Daratumumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4)…
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
- Trial name
- DAWN (NCT05403138)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in…
- Trial name
- NCT02028884
- Testing
- Satralizumab, Baseline Treatment
- Where
- 40 sites in United States, France and 9 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
- Trial name
- NCT07247292
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Neuromyelitis Optica Spectrum Disorder
Ofatumumab in AQP4-IgG Seropositive NMOSD
This is an open-label, single-arm, multicentre prospective pilot study to assess the efficacy and safety of ofatumumab in patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) in China.
- Trial name
- NCT05504694
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a multicenter, randomized, double-blind, placebo-controlled Phase Ⅱ study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with neuromyelitis optica…
- Trial name
- NCT05551598
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
NMO Spectrum Disorder
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
The primary objective of this registry study is to evaluate the therapeutic efficacy and safety profiles of distinct monoclonal antibody-based therapies for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum…
- Trial name
- NCT06885957
- Testing
- Mab Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
NMOSD
Comparative Study on AQP4 Antibody Detection Methods
This study aims to determine which method is more suitable for clinical application by comparing the sensitivity, specificity, and accuracy of serum AQP4-IgG detection using live cell CBA and fixed cell CBA methods, thereby…
- Trial name
- NCT06767020
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Neuromyelitis Optica Spectrum Disorders, Pain
Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol
Abstract Background Neuropathic pain is a common complication in neuromyelitis optica spectrum disorder (NMOSD), which seriously affects the quality of life of NMOSD patients, with no satisfactory treatment.
- Trial name
- NCT05871658
- Testing
- electroacupuncture
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Yuanqi Zhao,MD
Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation).
- Trial name
- PET-AON (NCT06453694)
- Testing
- Efgartigimod Alfa
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica Spectrum Related Disorders
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Devic's neuromyelitis optica (NMO) is rare. Epidemiological and demographic data are poor, based mainly on monocentric cohorts. Moreover, NMO might be difficult to distinguish from multiple sclerosis and begin with atypical or…
- Trial name
- NOMADMUS (NCT02850705)
- Where
- France
- Volunteers
- 1,787 people
- Sponsor
- Hospices Civils de Lyon
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
NMOSD is an autoimmune disease of the central nervous system that predominantly affects the spinal cord and optic nerves. The objectives of this study are to assess the efficacy and safety of FcRn antagonists (efgartigmod) for…
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
- Trial name
- FACT (NCT06497374)
- Testing
- Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disease (NMOSD)
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07592754
- Testing
- KSVCBD injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese PLA General Hospital
Neuromyelitis Optica Spectrum Disorder
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica…
- Trial name
- NCT05549258
- Testing
- Inebilizumab
- Where
- 19 sites in United States, Argentina and 9 more
- Volunteers
- 15 people
- Sponsor
- Amgen
Neuromyelitis Optica Spectrum Disorders, MOGAD
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in…
- Conditions
- Neuromyelitis Optica Spectrum Disorders, MOGAD, Multiple Sclerosis
- Trial name
- PoGe (NCT06865274)
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS